The small anticancer efficacy is only required to get RC220 out of the supportive care category and allow doctors to use it without having to fight with the insurance companies for hours on the phone getting prior authorisation. As long as the label says anticancer then it doesn’t matter how small the anticancer efficacy - this was for me the most surprising aspect of the Triangle report.
In the long term doctors will likely either reduce the dose of anthracycline they use and increase the amount of RC220 and/or increase the number of treatment cycles. Both of these will make RC220 much more effective as an anticancer agent.
Of course we should not forget m6A here which is a totally independent pathway to anticancer efficacy.
The small anticancer efficacy is only required to get RC220 out...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |